Role of basal inflammatory status as a predictor of survival in bevacizumab-treated advanced non-small cell lung cancer (NSCLC) patients.

被引：0
|
作者：
Botta, C.
Guglielmo, A.
Bestoso, E.
Apollinari, S.
Licchetta, A.
Blardi, P.
Tassone, P.
Chiriaco, G.
Barbieri, V.
Mantovani, G.
Tagliaferri, P.
Correale, P.
机构：
[1] Siena Univ Hosp, Ist Toscano Tumori, Med Oncol Unit, Dept Oncol, Siena, Italy
[2] Sect Med Oncol, Siena, Italy
[3] Siena Univ Hosp, Dept Clin Pharmacol, Siena, Italy
[4] Univ Catanzaro, Sch Med, Sect Med Oncol, Catanzaro, Italy
[5] Magna Graecia Univ Catanzaro, Med Oncol Unit, Catanzaro, Italy
[6] Tommaso Campanella Canc Ctr, Catanzaro, Italy
[7] Univ Cagliari, Dept Med Oncol, Cagliari, Italy
[8] Siena Univ Hosp, Dept Oncol, Med Oncol Unit, Siena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.7582
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7582
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Inflammatory status and prognosis of locally advanced non-small cell lung cancer
    Maria Galvan-Roman, Jose
    Curbelo, Jose
    Aspa, Javier
    JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 2782 - 2785
  • [42] Chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    LUNG CANCER, 2002, 38 : S47 - S50
  • [43] Improvement in Survival in Patients With Advanced Non-small Cell Lung Cancer
    Yoshida, Keishi
    Watanabe, Kaoru
    Nishimura, Taku
    Ikushima, Hiroaki
    Ohara, Sayaka
    Takeshima, Hideyuki
    Sakatani, Toshio
    Usui, Kazuhiro
    ANTICANCER RESEARCH, 2025, 45 (01) : 295 - 305
  • [44] PHASE II STUDY OF BIWEEKLY IRINOTECAN PLUS BEVACIZUMAB IN HEAVILY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Cardona, Andres F.
    Arrieta, Oscar
    Cuello, Mauricio
    Corrales, Luis
    Vargas, Carlos
    Martin, Claudio
    Carranza, Hernan
    Otero, Jorge M.
    Katherine Rodriguez, July
    Mas, Luis
    Archila, Pilar
    Bramuglia, Guillermo
    Pastran, Zulay
    Curcio, Elizabeth
    Rojas, Leonardo
    Bernal, Laura
    Campos Parra, Alma D.
    Giannikopoulos, Petros
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S881 - S882
  • [45] Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC)
    Heist, R. S.
    Fidias, P.
    Huberman, M.
    Temel, J.
    Sequist, L.
    Lynch, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
    Bonanno, Laura
    De Paoli, Angela
    Zulato, Elisabetta
    Esposito, Giovanni
    Calabrese, Fiorella
    Favaretto, Adolfo
    Santo, Antonio
    Del Conte, Alessandro
    Chilosi, Marco
    Oniga, Francesco
    Sozzi, Gabriella
    Moro, Massimo
    Ciccarese, Francesco
    Nardo, Giorgia
    Bertorelle, Roberta
    Candiotto, Cinzia
    De Salvo, Gian Luca
    Amadori, Alberto
    Conte, PierFranco
    Indraccolo, Stefano
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3316 - 3324
  • [47] Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
    Costantini, Adrien
    Julie, Catherine
    Dumenil, Coraline
    Helias-Rodzewicz, Zofia
    Dumoulin, Jennifer
    Giraud, Violaine
    Labrune, Sylvie
    Chinet, Thierry
    Emile, Jean-Francois
    Giroux-Leprieur, Etienne
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [48] Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC)
    Tassinari, D.
    Drudi, F.
    Carloni, F.
    Nicoletti, S.
    Possenti, C.
    Santelmo, C.
    Lazzari, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] The quantification of DNA in the serum is a useful prognostic factor in advanced non-small cell lung cancer (NSCLC) patients.
    Berrocal, A
    Sirera, R
    Camps, C
    Bremnes, RM
    Alberola, V
    Bayo, P
    Safont, MJ
    Blasco, A
    Taron, M
    Sanchez, JJ
    Rosell, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 669S - 669S
  • [50] Radiographic parameters in predicting outcome of patients with nonsquamous non-small cell lung cancer (NSCLC) treated with bevacizumab.
    Kaufman, Michael R.
    Salem, Mohamed E.
    Aoun, Hussein
    Kalemkerian, Gregory Peter
    Kunz, Sara
    El-Refai, Sherif
    Ranganath, Praveen
    Sukari, Ammar
    Gadgeel, Shirish M.
    Wozniak, Antoinette J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345